Yiwei Shen1, Bo Qu1,2, Nan Shen3,4,5,6,7. 1. Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Shandong Middle Road, Shanghai, 200001, China. 2. Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, 518040, China. 3. Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Shandong Middle Road, Shanghai, 200001, China. Nan.Shen@cchmc.org. 4. Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, 518040, China. Nan.Shen@cchmc.org. 5. Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Nan.Shen@cchmc.org. 6. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Nan.Shen@cchmc.org. 7. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, 200032, China. Nan.Shen@cchmc.org.
Abstract
PURPOSE OF REVIEW: The exact pathogenesis of systemic lupus erythematosus (SLE) remains unclear. Accumulating finds have indicated the roles of the non-coding RNAs (ncRNAs) acting as novel epigenetic regulatory elements in the dysfunction of the immune system in SLE. This review will introduce recent studies on how ncRNAs are involved in the development of SLE. RECENT FINDINGS: Recent advances in ncRNAs biology have greatly expanded our understanding of epigenetic regulation of immune responses and inflammation, and increasing evidence suggests ncRNAs are important players in SLE development. Identifications of abnormal expression patterns of ncRNAs and relevant biological impacts in lupus patients have revealed their potential as novel biomarkers and therapeutic targets for SLE. The dysregulation of ncRNAs contributes to the immunopathogenesis of SLE. Clarifying the functions and mechanisms of SLE-associated ncRNAs provides new opportunities for disease biomarkers and targeted therapies.
PURPOSE OF REVIEW: The exact pathogenesis of systemic lupus erythematosus (SLE) remains unclear. Accumulating finds have indicated the roles of the non-coding RNAs (ncRNAs) acting as novel epigenetic regulatory elements in the dysfunction of the immune system in SLE. This review will introduce recent studies on how ncRNAs are involved in the development of SLE. RECENT FINDINGS: Recent advances in ncRNAs biology have greatly expanded our understanding of epigenetic regulation of immune responses and inflammation, and increasing evidence suggests ncRNAs are important players in SLE development. Identifications of abnormal expression patterns of ncRNAs and relevant biological impacts in lupus patients have revealed their potential as novel biomarkers and therapeutic targets for SLE. The dysregulation of ncRNAs contributes to the immunopathogenesis of SLE. Clarifying the functions and mechanisms of SLE-associated ncRNAs provides new opportunities for disease biomarkers and targeted therapies.
Authors: Di Yu; Sudha Rao; Louis M Tsai; Sau K Lee; Yiqing He; Elissa L Sutcliffe; Monika Srivastava; Michelle Linterman; Lei Zheng; Nicholas Simpson; Julia I Ellyard; Ian A Parish; Cindy S Ma; Qi-Jing Li; Christopher R Parish; Charles R Mackay; Carola G Vinuesa Journal: Immunity Date: 2009-07-23 Impact factor: 31.745
Authors: Lasse S Kristensen; Maria S Andersen; Lotte V W Stagsted; Karoline K Ebbesen; Thomas B Hansen; Jørgen Kjems Journal: Nat Rev Genet Date: 2019-08-08 Impact factor: 53.242
Authors: Walter K Mowel; Jonathan J Kotzin; Sam J McCright; Vanessa D Neal; Jorge Henao-Mejia Journal: Trends Immunol Date: 2017-09-14 Impact factor: 16.687